Results 211 to 220 of about 19,955 (310)

Global Burden of Major Urologic Diseases in Women, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. [PDF]

Int J Womens Health
Zhang J, Shen J, Chen Z, Lu L, Wang J.
europepmc   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications. [PDF]

Curr Oncol
Somoto T, Utsumi T, Ikeda R, Ishitsuka N, Noro T, Suzuki Y, Iijima S, Sugizaki Y, Oka R, Endo T, Kamiya N, Suzuki H.   +11 more
europepmc   +1 more source

Urincholesterinbestimmung im Rahmen der Früherkennung und Verlaufskontrolle von Harnblasentumoren [PDF]

, 1984
Bichler, K.-H., Jüngst, Dieter, Tauber, R.   +2 more
core   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, Volume 20, Issue 3, Page 823-837, March 2026.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Expression of Nectin‐4 and Trop‐2 in upper tract urothelial carcinoma: implications for biomarker‐driven antibody‐drug conjugate therapy

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Recent advancements in antibody‐drug conjugates, including FDA‐approved therapies targeting Nectin‐4 and Trop‐2, have transformed the cancer treatment landscape, including upper tract urothelial carcinoma (UTUC). However, varied treatment effects and drug‐associated adverse effects raise the question of whether patients should be selected ...
Ping Shi, Qingqing Wu, Yong Zhang, Tiane Chen, Joshua I. Warrick, David J. DeGraff, Jay D. Raman, Guoli Chen   +7 more
wiley   +1 more source

Association of race and 30-day postoperative complications after urologic oncology surgery. [PDF]

Can Urol Assoc J
Bak AB, Pace KJC, Gao B, Wallis CJD, Lee JY.   +4 more
europepmc   +1 more source

Post hoc estimation of a quantitative restriction spectrum imaging biomarker for prostate cancer detection using conventional MRI

Journal of Applied Clinical Medical Physics, Volume 27, Issue 3, March 2026.
Abstract Background Multiparametric MRI is useful for early detection of clinically significant prostate cancer (csPCa), but its standard apparent diffusion coefficient (ADC) has limited utility as a quantitative metric for automated, patient‐level detection of csPCa.
Deondre D. Do, Christopher C. Conlin, Aditya Bagrodia, Matthew Cooperberg, Michael E. Hahn, Mukesh Harisinghani, Gary Hollenberg, Juan Javier‐Desloges, Sophia C. Kamran, Christopher J. Kane, Kang‐Lung Lee, Michael A. Liss, Daniel J. A. Margolis, Paul M. Murphy, Nabih Nakrour, Michael A. Ohliger, Thomas Osinski, Rebecca Rakow‐Penner, Mariluz Rojo Domingo, Amirali Salmasi, Ahmed S. Shabaik, Yuze Song, Shaun Trecarten, Natasha Wehrli, Eric P. Weinberg, Sean Woolen, Anders M. Dale, Tyler M. Seibert   +27 more
wiley   +1 more source

Readability Optimization of Layperson Summaries in Urological Oncology Clinical Trials: Outcomes from the BRIDGE-AI 8 Study. [PDF]

Curr Oncol
Cano I, Pannu A, Layne E, Ganjavi C, Desai A, Miranda G, Cai J, Magoulianitis V, Gill K, Fuchs G, Desai M, Gill I, Cacciamani GE.   +12 more
europepmc   +1 more source

Intercellular Horizontal Transfer of TXNDC5 mRNA via Extracellular Vesicles Contributes to Tumor‐Associated Macrophage‐Mediated Prostate Cancer Metastasis

Advanced Science, Volume 13, Issue 13, 3 March 2026.
This study investigates the role of M2 macrophage‐derived extracellular vesicles (M2 EVs) in prostate cancer (PCa) metastasis. Mechanistically, M2 EVs horizontally transfer TXNDC5 mRNA to PCa cells, where the molecule induces the mesenchymal‐like state (MLS), enhancing PCa migration and invasion.
Cong Hu, Tianyang Wu, Jiayi Wang, Xinxing Du, Xinrui Wu, Yanhao Dong, Zehong Peng, Penghui Liao, Zirui Guo, Zheyu Liu, Kenneth J Pienta, Yinjie Zhu, Jiahua Pan, Liang Dong, Wei Xue   +14 more
wiley   +1 more source